Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma.

IF 3.9 3区工程技术 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Biomedicines Pub Date : 2024-11-14 DOI:10.3390/biomedicines12112606

Christa N Grant, Carson A Wills, Xiaoming Liu, Longgui Chen, Zhenqiu Liu, Hong-Gang Wang

{"title":"Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma.","authors":"Christa N Grant, Carson A Wills, Xiaoming Liu, Longgui Chen, Zhenqiu Liu, Hong-Gang Wang","doi":"10.3390/biomedicines12112606","DOIUrl":null,"url":null,"abstract":"Background: Neuroblastoma is a common pediatric solid tumor with poor outcomes in high-risk patients. The identification of new therapeutic biomarkers is critical for the treatment of disease.Methods: An analysis of large publicly available datasets of tumor gene expression was performed. In vivo studies were performed to elucidate the role of contactin-1 (CNTN1) in tumor progression.Results: Expression of the glycoprotein CNTN1 is elevated in neuroblastoma compared to other tumor types. CNTN1 expression is higher in stage 1 and non-MYCN-amplified tumors, compared to more aggressive stage 4 and MYCN-amplified tumors. Moreover, high CNTN1 expression is associated with increased overall survival in neuroblastoma patients. In vivo studies demonstrate reduced metastasis in mice xenografted with CNTN1 knockout tumors compared to wildtype.Conclusions: The results of this study suggest that CNTN1 is a potential biomarker and therapeutic target in neuroblastoma. Further investigation of CNTN1 could have significant clinical implications for improving neuroblastoma treatment.","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"12 11","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicines","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/biomedicines12112606","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neuroblastoma is a common pediatric solid tumor with poor outcomes in high-risk patients. The identification of new therapeutic biomarkers is critical for the treatment of disease.

Methods: An analysis of large publicly available datasets of tumor gene expression was performed. In vivo studies were performed to elucidate the role of contactin-1 (CNTN1) in tumor progression.

Results: Expression of the glycoprotein CNTN1 is elevated in neuroblastoma compared to other tumor types. CNTN1 expression is higher in stage 1 and non-MYCN-amplified tumors, compared to more aggressive stage 4 and MYCN-amplified tumors. Moreover, high CNTN1 expression is associated with increased overall survival in neuroblastoma patients. In vivo studies demonstrate reduced metastasis in mice xenografted with CNTN1 knockout tumors compared to wildtype.

Conclusions: The results of this study suggest that CNTN1 is a potential biomarker and therapeutic target in neuroblastoma. Further investigation of CNTN1 could have significant clinical implications for improving neuroblastoma treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将接触素-1 鉴定为神经母细胞瘤的潜在生物标记物和治疗靶点

背景：神经母细胞瘤是一种常见的儿科实体瘤，高危患者的预后较差。确定新的治疗生物标志物对疾病的治疗至关重要：方法：对可公开获得的大型肿瘤基因表达数据集进行了分析。方法：对可公开获得的大型肿瘤基因表达数据集进行了分析，并进行了体内研究，以阐明接触素-1（CNTN1）在肿瘤进展中的作用：结果：与其他肿瘤类型相比，神经母细胞瘤中糖蛋白 CNTN1 的表达升高。与侵袭性更强的4期和MYCN扩增肿瘤相比，CNTN1在1期和非MYCN扩增肿瘤中的表达更高。此外，CNTN1 的高表达与神经母细胞瘤患者总生存率的提高有关。体内研究表明，与野生型肿瘤相比，CNTN1基因敲除肿瘤异种移植小鼠的转移率降低：本研究结果表明，CNTN1 是神经母细胞瘤的潜在生物标志物和治疗靶点。对 CNTN1 的进一步研究可能对改善神经母细胞瘤的治疗具有重要的临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomedicines Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

5.20

自引率

8.50%

发文量

2823

审稿时长

8 weeks

期刊介绍： Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.